IXHL Incannex Healthcare Inc.

Nasdaq www.incannex.com


$ 0.35 $ 0.01 (2.56 %)    

Friday, 24-Oct-2025 15:48:33 EDT
QQQ $ 617.85 $ 1.84 (0.3 %)
DIA $ 472.36 $ 2.49 (0.53 %)
SPY $ 677.66 $ 1.19 (0.18 %)
TLT $ 91.46 $ -0.10 (-0.11 %)
GLD $ 377.58 $ -0.99 (-0.26 %)
$ 0.3409
$ 0.34
$ 0.35 x 400
$ 0.35 x 100
$ 0.34 - $ 0.36
$ 0.08 - $ 3.12
19,162,229
na
nm
$ 3.00
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 09-29-2025 06-30-2025 10-K
2 05-15-2025 03-31-2025 10-Q
3 02-14-2025 12-31-2024 10-Q
4 11-14-2024 09-30-2024 10-Q
5 09-30-2024 06-30-2024 10-K
6 05-15-2024 03-31-2024 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 incannex-healthcare-receives-180-day-extension-from-nasdaq-until-april-20-2026-to-regain-compliance-with-the-minimum-100-bid-price-requirement

MELBOURNE, Australia and NEW YORK, Oct. 22, 2025 (GLOBE NEWSWIRE) -- Incannex Healthcare Inc. (NASDAQ:IXHL), a clinical-stage p...

 incannex-healthcare-board-authorizes-share-repurchase-program-for-up-to-20m

Incannex Healthcare Inc. (NASDAQ:IXHL) ("Incannex" or the "Company"), a clinical-stage biopharmaceutical compan...

 incannex-announces-it-has-received-patient-reported-outcomes-and-phase-2-efficacy-data-for-ihl-42x-in-obstructive-sleep-apnoea-with-895-of-participants-describing-a-meaningful-change-to-their-lives

Incannex Healthcare Inc. (NASDAQ:IXHL), a clinical-stage pharmaceutical company developing innovative combination therapies for...

 nano-cap-incannexs-sleep-apnea-candidate-shows-effectiveness-and-safety-in-mid-stage-trial

Incannex's IHL-42X showed significant efficacy in Phase 2 sleep apnea trial, with strong AHI reduction, improved sleep, and...

 incannex-reports-phase-2-results-for-ihl-42x-reducing-sleep-apnea-severity-by-up-to-83-with-strong-safety-profile

Statistically and clinically significant improvements across key clinical endpoints; IHL-42X reduced AHI by up to 83% from base...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION